Compare CGTX & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGTX | OSUR |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.5M | 214.1M |
| IPO Year | 2021 | 2000 |
| Metric | CGTX | OSUR |
|---|---|---|
| Price | $1.14 | $3.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $3.33 | $3.00 |
| AVG Volume (30 Days) | ★ 624.0K | 422.9K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $167,064,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | $7.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $2.08 |
| 52 Week High | $3.83 | $4.22 |
| Indicator | CGTX | OSUR |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 64.06 |
| Support Level | $1.00 | $3.05 |
| Resistance Level | $1.19 | $3.31 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 80.56 | 96.53 |
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.